SCHEMBL23924832

SCHEMBL23924832

CC(C)c1ccccc1[C@@H]1CN(Cc2ccc3c(c2)OCC3)CCN1

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
CYP2D6 P10635 1/20 0.36
PRMT5 O14744 9/20 0.35
WDR77 Q9BQA1 9/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
KCNJ1 P48048 5/20 0.34
FAAH O00519 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25203235 1.00 LMNA (0.36) LMNACYP2D6PRMT5WDR77ALDH1A1
SCHEMBL25640465 0.89 CYP2D6 (0.48) LMNACYP2D6ALDH1A1FAAHTSHR
SCHEMBL25640538 0.85 LMNA (0.51) LMNAALDH1A1TSHRNPSR1
SCHEMBL25743441 0.85 LMNA (0.51) LMNAALDH1A1TSHRNPSR1
SCHEMBL30287271 0.84 LMNA (0.43) LMNACYP2D6ALDH1A1KCNJ1TSHR
SCHEMBL25190457 0.83 LMNA (0.37) LMNACYP2D6PRMT5WDR77KCNJ1
SCHEMBL23924923 0.83 LMNA (0.37) LMNACYP2D6PRMT5WDR77KCNJ1
SCHEMBL30034375 0.81 KMT2A (0.46) LMNAALDH1A1
SCHEMBL25192315 0.81 KMT2A (0.46) LMNAALDH1A1
SCHEMBL23943614 0.81 KMT2A (0.46) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270210-A1 BCL-2 Inhibitor BEIGENE, LTD. (KY) 2025-08-28 US disclosed
US-12286430-B2 Bcl-2 inhibitor BEIGENE, LTD. (KY) 2025-04-29 US disclosed
US-20240376097-A1 BCL-2 Inhibitor BEIGENE LTD. (KY) 2024-11-14 US disclosed
CN-116969936-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116969937-A BCL-2 inhibitors 百济神州有限公司 2023-10-31 CN disclosed
CN-116802179-A BCL-2 inhibitors 百济神州有限公司 2023-09-22 CN disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed
US-20230159522-A1 BCL-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2023-05-25 US disclosed
EP-4136084-A1 BCL-2 INHIBITOR BeiGene, Ltd. (KY) 2023-02-22 EP disclosed
WO-2021208963-A1 BCL-2 INHIBITOR BEIGENE, LTD. (KY) 2021-10-21 WO disclosed
WO-2021208963-A1 BCL-2 INHIBITOR BEIGENE, LTD. (KY) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270210-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 LMNA 2103/4885CYP2D6 2785/4885PRMT5 3348/4885
US-20230159522-A1 BCL-2 INHIBITOR BCL2, BCL2A1, BCL2L1 LMNA 2103/4885CYP2D6 2785/4885PRMT5 3348/4885
US-20240376097-A1 BCL-2 Inhibitor BCL2, BCL2A1, BCL2L1 LMNA 2103/4885CYP2D6 2785/4885PRMT5 3348/4885
US-12286430-B2 Bcl-2 inhibitor BCL2, BCL2A1, BCL2L1 LMNA 2103/4885CYP2D6 2785/4885PRMT5 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.